Nascent Biotech, Inc.

About Nascent Biotech, Inc.

Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.

Nascent Biotech is the home of the natural human antibody cancer product Pritimumab, which has been shown to fight rare forms of cancer successfully.

NBIO United States

0.279USD0.0081 (-2.90%)

• At close Thu Oct 06 2022

Other OTC exchange

Sector: Healthcare

Industry: Biotechnology

Location United States, Vero Beach

Grade: AEF

14,227,878 USD
BETA (5y)


for 5 years
for 3 years
for 2 years
for last year
for this year
Nascent Biotech, Inc.
© 2023 All rights reserved
Make with 🤎 and ☕ for you!

Investing involves risk, including possible loss of principal.

The strategies discussed are strictly for illustrative and educational purposes and are not a recommendation, offer or solicitation to buy or sell any securities or to adopt any investment strategy. There is no guarantee that any strategies discussed will be effective.

International investing involves risks, including risks related to foreign currency, limited liquidity, less government regulation and the possibility of substantial volatility due to adverse political, economic or other developments. These risks often are heightened for investments in emerging/ developing markets or in concentrations of single countries.